Protocol Ledger

NCT06155383 · Phase II · RECRUITING

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Interventional Phase II clinical trial protocol NCT06155383 sponsored by RemeGen Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-27 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06155383
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06155383
Protocol FieldVerified Registry Value
NCT IdentifierNCT06155383
Consolidated Lead SponsorRemeGen Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2023-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06155383
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Yunnan Cancer HospitalKunming, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Xiamen UniversityXiamen, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI